Product: Candida albicans IgM ELISA
Candida albicans IgM ELISA
Technology | ELISA |
Kit size | 96 Tests |
Sample material | Serum or Plasma |
Sample preparation | 1:101 predilution |
Sample volume | 5 µl |
Standard range | 1 – 150 U/ml |
Incubation | 60 min, 30 min, 20 min at RT |
Measuring system | TMB at 450 nm |
Sensitivity | 1.07 U/ml |
Special remarks: The DEMEDITEC Candida albicans IgM Antibody ELISA Test Kit has been designed for the the detection and the quantitative determination of specific IgM antibodies against Candida albicans in serum and plasma.
The antigens used for coating the microtiter plates are the somatic + metabolic ones, purified by dialysis.
Invasive candidal mycosis (synonyms: candidosis, candidiasis) account for more than 80% of the cases of deep-seated mycoses in Germany. This incidence is similar to those of other industrial countries. The main causative agent is the yeast Candida albicans, which is the only fungal species belonging to the „normal“ microflora. Candida albicans has a low pathogenic potential, which rarely allows it to infect a healthy host. Rather, in immunosuppressed patients it may cause several diseases as an opportunistic pathogen.In candidal mycosis three types of disease can be distinguished. First, Candida albicans can infect the skin and the mucous membranes of the outer genitals, mouth, respiratory tract and digestion tract. Second, skin and mucous membranes may be infected, encouraged by factors like pregnancy, diabetes mellitus, immunodeficiency and therapies with cytostatics or antibiotics. Third, the infestation of the inner organs, for example the lungs in a Candida sepsis can cause death in immunosuppressed patients with a cellular immunodeficiency.Serological tests are frequently used to ascertain the clinical significance of Candida spp. isolates. Rising titers of lgG antibodies to Candida albicans may reflect invasive candidiasis in immunocompetent patients. The detection of IgA and IgM antibodies is important to identify a fresh infection. Immunosuppressed patients often fail to produce antibodies, so a negative antibody test does not necessarily rule out the disease. In this case the use of an antigen detection test is recommended. Besides the detection of antibodies and antigen, the site of manifestation, the number of colony-forming units, and the concomitant use of antimycotics must be considered.
In order to avoid interference of rheumatoid factors, it is highly recommended that patient sera should be treated with RF absorbent (Cat.No. DE-MJS02). Alternatively, positive results can be confirmed in a second test run in the presence of RF adsorbent. Do not pre-treat the controls or standards with RF absorbent!





